{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:58:35Z","timestamp":1790744315995,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Mater."],"DOI":"10.1038\/s41563-026-02675-7","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T09:01:55Z","timestamp":1786525315000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An inherent T cell-activating mRNA delivery carrier for in vivo CAR T generation"],"prefix":"10.1038","author":[{"given":"Qiannan","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingli","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pijun","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9622-0870","authenticated-orcid":false,"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4364-2196","authenticated-orcid":false,"given":"Huapan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2482-3744","authenticated-orcid":false,"given":"Huayu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"2675_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62\u201368 (2015).","journal-title":"Science"},{"key":"2675_CR2","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrc.2016.97","volume":"16","author":"AD Fesnak","year":"2016","unstructured":"Fesnak, A. D., June, C. H. & Levine, B. L. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat. Rev. Cancer 16, 566\u2013581 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"2675_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker, D. J. et al. CAR T therapy beyond cancer: the evolution of a living drug. Nature 619, 707\u2013715 (2023).","journal-title":"Nature"},{"key":"2675_CR4","doi-asserted-by":"publisher","first-page":"809754","DOI":"10.3389\/fonc.2022.809754","volume":"12","author":"TQ Xin","year":"2022","unstructured":"Xin, T. Q. et al. In-vivo induced CAR-T cell for the potential breakthrough to overcome the barriers of current CAR-T cell therapy. Front. Oncol. 12, 809754 (2022).","journal-title":"Front. Oncol."},{"key":"2675_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41565-020-00822-y","volume":"16","author":"NQ Gong","year":"2021","unstructured":"Gong, N. Q. et al. Nanomaterials for T-cell cancer immunotherapy. Nat. Nanotechnol. 16, 25\u201336 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"2675_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).","journal-title":"Blood Cancer J."},{"key":"2675_CR7","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","volume":"40","author":"AJ Barbier","year":"2022","unstructured":"Barbier, A. J. et al. The clinical progress of mRNA vaccines and immunotherapies. Nat. Biotechnol. 40, 840\u2013854 (2022).","journal-title":"Nat. Biotechnol."},{"key":"2675_CR8","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41573-024-01042-y","volume":"23","author":"N Pardi","year":"2024","unstructured":"Pardi, N. & Krammer, F. mRNA vaccines for infectious diseases\u2014advances, challenges and opportunities. Nat. Rev. Drug Discov. 23, 838\u2013861 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2675_CR9","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41578-022-00529-7","volume":"8","author":"SA Dilliard","year":"2023","unstructured":"Dilliard, S. A. & Siegwart, D. J. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat. Rev. Mater. 8, 282\u2013300 (2023).","journal-title":"Nat. Rev. Mater."},{"key":"2675_CR10","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","volume":"40","author":"E Rohner","year":"2022","unstructured":"Rohner, E. et al. Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 40, 1586\u20131600 (2022).","journal-title":"Nat. Biotechnol."},{"key":"2675_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121339","volume":"281","author":"A Kheirolomoom","year":"2022","unstructured":"Kheirolomoom, A. et al. In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift. Biomaterials 281, 121339 (2022).","journal-title":"Biomaterials"},{"key":"2675_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotechnol. 15, 313\u2013320 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"2675_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42672-x","volume":"14","author":"ZJ Li","year":"2023","unstructured":"Li, Z. J. et al. Charge-altering releasable transporters enhance mRNA delivery in vitro and exhibit in vivo tropism. Nat. Commun. 14, 6983 (2023).","journal-title":"Nat. Commun."},{"key":"2675_CR14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nrc3565","volume":"13","author":"MH Kershaw","year":"2013","unstructured":"Kershaw, M. H., Westwood, J. A. & Darcy, P. K. Gene-engineered T cells for cancer therapy. Nat. Rev. Cancer 13, 525\u2013541 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"2675_CR15","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1038\/s41565-024-01781-4","volume":"19","author":"EB Zhu","year":"2024","unstructured":"Zhu, E. B. et al. Biomimetic cell stimulation with a graphene oxide antigen-presenting platform for developing T cell-based therapies. Nat. Nanotechnol. 19, 1914\u20131922 (2024).","journal-title":"Nat. Nanotechnol."},{"key":"2675_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13997-3","volume":"11","author":"JC Charpentier","year":"2020","unstructured":"Charpentier, J. C. et al. Macropinocytosis drives T cell growth by sustaining the activation of mTORC1. Nat. Commun. 11, 180 (2020).","journal-title":"Nat. Commun."},{"key":"2675_CR17","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.cels.2024.11.007","volume":"15","author":"E Ariail","year":"2024","unstructured":"Ariail, E. et al. Emerging approaches for T cell-stimulating platform development. Cell Syst. 15, 1198\u20131208 (2024).","journal-title":"Cell Syst."},{"key":"2675_CR18","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41563-024-01825-z","volume":"23","author":"JQ Shi","year":"2024","unstructured":"Shi, J. Q. et al. Lyophilized lymph nodes for improved delivery of chimeric antigen receptor T cells. Nat. Mater. 23, 844\u2013853 (2024).","journal-title":"Nat. Mater."},{"key":"2675_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201807359","volume":"31","author":"JW Hickey","year":"2019","unstructured":"Hickey, J. W. et al. Engineering an artificial T-cell stimulating matrix for immunotherapy. Adv. Mater. 31, e1807359 (2019).","journal-title":"Adv. Mater."},{"key":"2675_CR20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201966","volume":"219","author":"M Shakiba","year":"2021","unstructured":"Shakiba, M. et al. TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. J. Exp. Med. 219, e20201966 (2021).","journal-title":"J. Exp. Med."},{"key":"2675_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1158\/1538-7445.AM2022-3869","volume":"82","author":"P Goral","year":"2022","unstructured":"Goral, P. et al. A human T cell exhaustion model for assessing immuno-oncology therapies. Cancer Res. 82, 89\u2013101 (2022).","journal-title":"Cancer Res."},{"key":"2675_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27078-x","volume":"12","author":"HP Fang","year":"2021","unstructured":"Fang, H. P. et al. Combination of epigenetic regulation with gene therapy-mediated immune checkpoint blockade induces anti-tumour effects and immune response in vivo. Nat. Commun. 12, 6742 (2021).","journal-title":"Nat. Commun."},{"key":"2675_CR23","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41551-021-00786-x","volume":"5","author":"MP Lokugamage","year":"2021","unstructured":"Lokugamage, M. P. et al. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nat. Biomed. Eng. 5, 1059\u20131068 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"2675_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf4398","volume":"7","author":"M Kim","year":"2021","unstructured":"Kim, M. et al. Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver. Sci. Adv. 7, eabf4398 (2021).","journal-title":"Sci. Adv."},{"key":"2675_CR25","doi-asserted-by":"publisher","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","volume":"15","author":"KJ Kauffman","year":"2015","unstructured":"Kauffman, K. J. et al. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Lett. 15, 7300\u20137306 (2015).","journal-title":"Nano Lett."},{"key":"2675_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202405444","volume":"63","author":"XY Zhang","year":"2024","unstructured":"Zhang, X. Y. et al. One-component cationic lipids for systemic mRNA delivery to splenic T cells. Angew. Chem. Int. Ed. 63, e202405444 (2024).","journal-title":"Angew. Chem. Int. Ed."},{"key":"2675_CR27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jconrel.2021.11.022","volume":"341","author":"JR Melamed","year":"2022","unstructured":"Melamed, J. R. et al. Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery. J. Control. Release 341, 206\u2013214 (2022).","journal-title":"J. Control. Release"},{"key":"2675_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50093-7","volume":"15","author":"K Su","year":"2024","unstructured":"Su, K. et al. Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation. Nat. Commun. 15, 5659 (2024).","journal-title":"Nat. Commun."},{"key":"2675_CR29","doi-asserted-by":"publisher","first-page":"11992","DOI":"10.1021\/jacs.8b05341","volume":"140","author":"HP Fang","year":"2018","unstructured":"Fang, H. P. et al. Molecular strings significantly improved the gene transfection efficiency of polycations. J. Am. Chem. Soc. 140, 11992\u201312000 (2018).","journal-title":"J. Am. Chem. Soc."},{"key":"2675_CR30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2109256118","volume":"118","author":"SA Dilliard","year":"2021","unstructured":"Dilliard, S. A., Cheng, Q. & Siegwart, D. J. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc. Natl Acad. Sci. USA 118, e2109256118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2675_CR31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2116271119","volume":"119","author":"M Qiu","year":"2022","unstructured":"Qiu, M. et al. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc. Natl Acad. Sci. USA 119, e2116271119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2675_CR32","doi-asserted-by":"publisher","first-page":"8392","DOI":"10.1021\/acsnano.3c13039","volume":"18","author":"ND Le","year":"2024","unstructured":"Le, N. D. et al. Antiangiogenic therapeutic mRNA delivery using lung-selective polymeric nanomedicine for lung cancer treatment. ACS Nano 18, 8392\u20138410 (2024).","journal-title":"ACS Nano"},{"key":"2675_CR33","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nnano.2016.269","volume":"12","author":"F Chen","year":"2017","unstructured":"Chen, F. et al. Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. Nat. Nanotechnol. 12, 387\u2013393 (2017).","journal-title":"Nat. Nanotechnol."},{"key":"2675_CR34","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/s41565-018-0344-3","volume":"14","author":"VP Vu","year":"2019","unstructured":"Vu, V. P. et al. Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles. Nat. Nanotechnol. 14, 260\u2013268 (2019).","journal-title":"Nat. Nanotechnol."},{"key":"2675_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202007421","volume":"33","author":"ARK Kumar","year":"2021","unstructured":"Kumar, A. R. K. et al. Materials for improving immune cell transfection. Adv. Mater. 33, e2007421 (2021).","journal-title":"Adv. Mater."},{"key":"2675_CR36","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/pharmaceutics17030303","volume":"17","author":"JJ Mata-Molanes","year":"2025","unstructured":"Mata-Molanes, J. J. et al. A quantitative approach to potency testing for chimeric antigen receptor-encoding lentiviral vectors and autologous CAR-T cell products, using flow cytometry. Pharmaceutics 17, 303 (2025).","journal-title":"Pharmaceutics"},{"key":"2675_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202313226","volume":"36","author":"AE Metzloff","year":"2024","unstructured":"Metzloff, A. E. et al. Antigen presenting cell mimetic lipid nanoparticles for rapid mRNA CAR T cell cancer immunotherapy. Adv. Mater. 36, e2313226 (2024).","journal-title":"Adv. Mater."},{"key":"2675_CR38","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/eji.201646837","volume":"47","author":"D Cibri\u00e1n","year":"2017","unstructured":"Cibri\u00e1n, D. & S\u00e1nchez-Madrid, F. CD69: from activation marker to metabolic gatekeeper. Eur. J. Immunol. 47, 946\u2013953 (2017).","journal-title":"Eur. J. Immunol."},{"key":"2675_CR39","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41577-025-01238-2","volume":"26","author":"D Masopust","year":"2026","unstructured":"Masopust, D. et al. Guidelines for T cell nomenclature. Nat. Rev. Immunol. 26, 298\u2013313 (2026).","journal-title":"Nat. Rev. Immunol."},{"key":"2675_CR40","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1038\/s12276-025-01516-y","volume":"57","author":"JO Choi","year":"2025","unstructured":"Choi, J. O., Seo, Y. & Hwang, S. S. Guardians of silence: transcriptional networks in T cell quiescence. Exp. Mol. Med. 57, 1663\u20131672 (2025).","journal-title":"Exp. Mol. Med."},{"key":"2675_CR41","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41596-019-0249-0","volume":"15","author":"DKY Zhang","year":"2020","unstructured":"Zhang, D. K. Y., Cheung, A. S. & Mooney, D. J. Activation and expansion of human T cells using artificial antigen-presenting cell scaffolds. Nat. Protoc. 15, 773\u2013798 (2020).","journal-title":"Nat. Protoc."},{"key":"2675_CR42","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","volume":"30","author":"D Sommermeyer","year":"2016","unstructured":"Sommermeyer, D. et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30, 492\u2013500 (2016).","journal-title":"Leukemia"},{"key":"2675_CR43","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1182\/blood-2006-10-051318","volume":"109","author":"A Perez-Diez","year":"2007","unstructured":"Perez-Diez, A. et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109, 5346\u20135354 (2007).","journal-title":"Blood"},{"key":"2675_CR44","doi-asserted-by":"publisher","first-page":"737","DOI":"10.4049\/jimmunol.142.3.737","volume":"142","author":"R Hirsch","year":"1989","unstructured":"Hirsch, R. et al. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J. Immunol. 142, 737\u2013743 (1989).","journal-title":"J. Immunol."},{"key":"2675_CR45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/CJI.0000000000000402","volume":"45","author":"G Lamture","year":"2022","unstructured":"Lamture, G. et al. TCR-independent activation in presence of a Src-family kinase inhibitor improves CAR-T cell product attributes. J. Immunother. 45, 139\u2013149 (2022).","journal-title":"J. Immunother."},{"key":"2675_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.electacta.2022.141783","volume":"470","author":"H Ida","year":"2023","unstructured":"Ida, H. et al. Surface morphology live-cell imaging reveals how macropinocytosis inhibitors affect membrane dynamics. Electrochim. Acta 470, 141783 (2023).","journal-title":"Electrochim. Acta"},{"key":"2675_CR47","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nri3198","volume":"12","author":"H Chi","year":"2012","unstructured":"Chi, H. Regulation and function of mTOR signalling in T cell fate decisions. Nat. Rev. Immunol. 12, 325\u2013338 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"2675_CR48","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.cmet.2019.03.005","volume":"29","author":"JW Jung","year":"2019","unstructured":"Jung, J. W. et al. Transmembrane 4 L Six Family Member 5 senses arginine for mTORC1 signalling. Cell Metab. 29, 1306\u20131319 (2019).","journal-title":"Cell Metab."},{"key":"2675_CR49","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/hep.22777","volume":"49","author":"SA Lee","year":"2009","unstructured":"Lee, S. A. et al. Blockade of Four-Transmembrane L6 Family Member 5 (TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative. Hepatology 49, 1316\u20131325 (2009).","journal-title":"Hepatology"},{"key":"2675_CR50","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1091\/mbc.e06-12-1109","volume":"18","author":"S Floyd","year":"2007","unstructured":"Floyd, S. et al. The insulin-like growth factor-I-mTOR signalling pathway induces the mitochondrial pyrimidine nucleotide carrier to promote cell growth. Mol. Biol. Cell 18, 3545\u20133555 (2007).","journal-title":"Mol. Biol. Cell"},{"key":"2675_CR51","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1158\/0008-5472.CAN-05-1580","volume":"66","author":"T Ikezoe","year":"2006","unstructured":"Ikezoe, T. et al. The longitudinal inhibition of PI3K\/Akt\/mTOR signalling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Cancer Res. 66, 673\u2013682 (2006).","journal-title":"Cancer Res."},{"key":"2675_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22126-y","volume":"12","author":"E Bonsergent","year":"2021","unstructured":"Bonsergent, E. et al. Quantitative characterization of extracellular vesicle uptake and content delivery within mammalian cells. Nat. Commun. 12, 1864 (2021).","journal-title":"Nat. Commun."},{"key":"2675_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26052-x","volume":"12","author":"L Liu","year":"2021","unstructured":"Liu, L. et al. Cell membrane coating integrity affects the internalization mechanism of biomimetic nanoparticles. Nat. Commun. 12, 5726 (2021).","journal-title":"Nat. Commun."},{"key":"2675_CR54","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1038\/sj.onc.1210797","volume":"27","author":"R Vasilcanu","year":"2008","unstructured":"Vasilcanu, R. et al. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and \u03b2-arrestin1. Oncogene 27, 1629\u20131638 (2008).","journal-title":"Oncogene"},{"key":"2675_CR55","doi-asserted-by":"crossref","unstructured":"Wu, Q. et al. IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms. J. Immunother. Cancer 9, e002722 (2021).","DOI":"10.1136\/jitc-2021-002722"},{"key":"2675_CR56","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1182\/blood-2007-03-080796","volume":"111","author":"J Tamburini","year":"2008","unstructured":"Tamburini, J. et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase\/Akt by up-regulating insulin-like growth factor-1 receptor signalling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 111, 379\u2013382 (2008).","journal-title":"Blood"},{"key":"2675_CR57","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nnano.2017.57","volume":"12","author":"TT Smith","year":"2017","unstructured":"Smith, T. T. et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat. Nanotechnol. 12, 813\u2013820 (2017).","journal-title":"Nat. Nanotechnol."},{"key":"2675_CR58","doi-asserted-by":"crossref","unstructured":"Li, Y.-R., Zhu, Y., Halladay, T. & Yang, L. In vivo CAR engineering for immunotherapy. Nat. Rev. Immunol. 25, 725\u2013744 (2025).","DOI":"10.1038\/s41577-025-01174-1"},{"key":"2675_CR59","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396 (2022).","journal-title":"Science"},{"key":"2675_CR60","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","volume":"573","author":"H Aghajanian","year":"2019","unstructured":"Aghajanian, H. et al. Targeting cardiac fibrosis with engineered T cells. Nature 573, 430\u2013433 (2019).","journal-title":"Nature"},{"key":"2675_CR61","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.2174\/156652412803833607","volume":"12","author":"M Jacob","year":"2012","unstructured":"Jacob, M., Chang, L. & Pur\u00e9, E. Fibroblast activation protein in remodeling tissues. Curr. Mol. Med. 12, 1220\u20131243 (2012).","journal-title":"Curr. Mol. Med."},{"key":"2675_CR62","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1237","volume":"11","author":"B Ng","year":"2019","unstructured":"Ng, B. et al. Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis. Sci. Transl. Med. 11, eaaw1237 (2019).","journal-title":"Sci. Transl. Med."},{"key":"2675_CR63","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf4696","volume":"9","author":"P D\u00e9sog\u00e8re","year":"2017","unstructured":"D\u00e9sog\u00e8re, P. et al. Type I collagen\u2013targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Sci. Transl. Med. 9, eaaf4696 (2017).","journal-title":"Sci. Transl. Med."},{"key":"2675_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59093-7","volume":"16","author":"J Yan","year":"2025","unstructured":"Yan, J. et al. Targeted immunotherapy rescues pulmonary fibrosis by reducing activated fibroblasts and regulating alveolar cell profile. Nat. Commun. 16, 3748 (2025).","journal-title":"Nat. Commun."},{"key":"2675_CR65","doi-asserted-by":"publisher","first-page":"1444964","DOI":"10.3389\/fimmu.2024.1444964","volume":"15","author":"ZL Ge","year":"2024","unstructured":"Ge, Z. L. et al. Macrophage polarization and its impact on idiopathic pulmonary fibrosis. Front. Immunol. 15, 1444964 (2024).","journal-title":"Front. Immunol."},{"key":"2675_CR66","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.molmed.2016.02.004","volume":"22","author":"AJ Byrne","year":"2016","unstructured":"Byrne, A. J., Maher, T. M. & Lloyd, C. M. Pulmonary macrophages: a new therapeutic pathway in fibrosing lung disease? Trends Mol. Med. 22, 303\u2013316 (2016).","journal-title":"Trends Mol. Med."},{"key":"2675_CR67","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signalling of chimeric antigen receptors. Nat. Med. 21, 581\u2013590 (2015).","journal-title":"Nat. Med."},{"key":"2675_CR68","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","volume":"28","author":"S Agarwal","year":"2020","unstructured":"Agarwal, S. et al. In vivo generation of CAR T cells selectively in human CD4+ lymphocytes. Mol. Ther. 28, 1783\u20131794 (2020).","journal-title":"Mol. Ther."},{"key":"2675_CR69","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.trecan.2024.07.009","volume":"10","author":"E Montauti","year":"2024","unstructured":"Montauti, E., Oh, D. Y. & Fong, L. CD4+ T cells in antitumor immunity. Trends Cancer 10, 969\u2013985 (2024).","journal-title":"Trends Cancer"},{"key":"2675_CR70","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","volume":"39","author":"AA Fitzgerald","year":"2020","unstructured":"Fitzgerald, A. A. & Weiner, L. M. The role of fibroblast activation protein in health and malignancy. Cancer Metast. Rev. 39, 783\u2013803 (2020).","journal-title":"Cancer Metast. Rev."},{"key":"2675_CR71","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/ITT.S291767","volume":"10","author":"R Bughda","year":"2021","unstructured":"Bughda, R. et al. Fibroblast Activation Protein (FAP)-targeted CAR-T cells: launching an attack on tumor stroma. Immunotargets Ther. 10, 313\u2013323 (2021).","journal-title":"Immunotargets Ther."},{"key":"2675_CR72","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.ymthe.2024.12.019","volume":"33","author":"HM Nguyen","year":"2025","unstructured":"Nguyen, H. M. et al. mRNA-LNPs induce immune activation and cytokine release in human whole blood assays across diverse health conditions. Mol. Ther. 33, 2872\u20132885 (2025).","journal-title":"Mol. Ther."},{"key":"2675_CR73","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","volume":"2","author":"LCS Wang","year":"2014","unstructured":"Wang, L. C. S. et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol. Res. 2, 154\u2013166 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"2675_CR74","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1158\/2326-6066.CIR-15-0263","volume":"4","author":"K Newick","year":"2016","unstructured":"Newick, K. et al. Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase A localization. Cancer Immunol. Res. 4, 541\u2013551 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"2675_CR75","doi-asserted-by":"publisher","first-page":"330","DOI":"10.4161\/cbt.11.3.14099","volume":"11","author":"SA Lee","year":"2011","unstructured":"Lee, S. A. et al. Differential inhibition of transmembrane 4 L six family member 5 (TM4SF5)-mediated tumorigenesis by TSAHC and sorafenib. Cancer Biol. Ther. 11, 330\u2013336 (2011).","journal-title":"Cancer Biol. Ther."}],"updated-by":[{"DOI":"10.1038\/s41563-026-02753-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000}}],"container-title":["Nature Materials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41563-026-02675-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41563-026-02675-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41563-026-02675-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:24:52Z","timestamp":1790742292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41563-026-02675-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":75,"alternative-id":["2675"],"URL":"https:\/\/doi.org\/10.1038\/s41563-026-02675-7","relation":{},"ISSN":["1476-1122","1476-4660"],"issn-type":[{"value":"1476-1122","type":"print"},{"value":"1476-4660","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41563-026-02753-w","URL":"https:\/\/doi.org\/10.1038\/s41563-026-02753-w","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}